A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.
Also called NCT05878561
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 248 participants
- Registry
-
NCT05878561
-
- Other papers using this trial's data
- Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05878561. Randomized; double masking; primary purpose treatment. Start 2022-11-09 (actual); primary completion 2024-12-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy
- Condition
- Essential Hypertension
- Intervention (Drug)
- Fimasartan + Indapamide
- Intervention (Drug)
- Fimasartan + Indapamide placebo
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct05878561- Content hash
77784bc903fed03e9f313b7ea36f0c970f419537d00e16e110d1df73d9aceae1